Uptake of active surveillance for very-low-risk prostate cancer in Sweden

JAMA Oncology

Volumn 3, Issue 10, 2017, Pages 1393-1398

  Loeb, Stacy ^a,b   Folkvaljon, Yasin ^c   Curnyn, Caitlin ^a,b   Robinson, David ^d,e   Bratt, Ola ^f,g   Stattin, Pär ^e,h  

^a NEW YORK UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^d RYHOV COUNTY HOSPITAL   (Sweden)

^e UMEÅ UNIVERSITY   (Sweden)

^f ADDENBROOKE S HOSPITAL   (United Kingdom)

^g LUND UNIVERSITY   (Sweden)

^h UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN;

ADULT; AGED; ARTICLE; CANCER RISK; COMORBIDITY; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; GLEASON SCORE; HUMAN; INFORMED CONSENT; MALE; MIDDLE AGED; POPULATION RESEARCH; PROSTATE BIOPSY; PROSTATE CANCER; SWEDEN; CANCER GRADING; CANCER STAGING; EARLY CANCER DIAGNOSIS; EPIDEMIOLOGY; METABOLISM; PROSTATIC NEOPLASMS; STATISTICS AND NUMERICAL DATA; VERY ELDERLY; WATCHFUL WAITING;

AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM STAGING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SWEDEN; WATCHFUL WAITING;

EID: 85015918653     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2016.3600     Document Type: Article

References (14)

1. Cooperberg MR, Carroll PR. Trends in management for patients with localized prostate cancer, 1990-2013. JAMA. 2015;314(1):80-82.
2. Roth JA, Gulati R, Gore JL, Cooperberg MR, Etzioni R. Economic analysis of prostate-specific antigen screening and selective treatment strategies. JAMA Oncol. 2016;2(7):890-898.
3. Jonsson H, Holmström B, Duffy SW, Stattin P. Uptake of prostate-specific antigen testing for early prostate cancer detection in Sweden. Int J Cancer. 2011;129(8):1881-1888.
4. Nordström T, Aly M, Clements MS, Weibull CE, Adolfsson J, Grönberg H. Prostate-specific antigen (PSA) testing is prevalent and increasing in Stockholm County, Sweden, despite no recommendations for PSA screening: results from a population-based study, 2003-2011. Eur Urol. 2013;63(3):419-425.
5. Loeb S, Berglund A, Stattin P. Population based study of use and determinants of active surveillance and watchful waiting for low and intermediate risk prostate cancer. J Urol. 2013;190(5):1742-1749.
6. Tomic K, Berglund A, Robinson D, et al. Capture rate and representativity of The National Prostate Cancer Register of Sweden. Acta Oncol. 2015;54(2):158-163.
7. Van Hemelrijck M, Wigertz A, Sandin F, et al; NPCR and PCBaSe Sweden. Cohort profile: the National Prostate Cancer Register of Sweden and Prostate Cancer Data Base Sweden 2.0. Int J Epidemiol. 2013;42(4):956-967.
8. Bratt O, Folkvaljon Y, Loeb S, Klotz L, Egevad L, Stattin P. Upper limit of cancer extent on biopsy defining very-low-risk prostate cancer. BJU Int. 2015;116(2):213-219.
9. Womble PR, Montie JE, Ye Z, Linsell SM, Lane BR, Miller DC; Michigan Urological Surgery Improvement Collaborative. Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. Eur Urol. 2015;67(1): 44-50.
10. Ingimarsson JP, Celaya MO, Laviolette M, Rees JR, Hyams ES. Trends in initial management of prostate cancer in New Hampshire. Cancer Causes Control. 2015;26(6):923-929.
11. Nationella Prostatacancerregistret. Välkommen till NPCR Nationella Prostatacancerregistret. http://www.npcr.se. Accessed June 1, 2016.
12. Stattin P, Sandin F, Sandbäck T, et al. Dashboard report on performance on select quality indicators to cancer care providers. Scand J Urol. 2016;50(1):21-28.
13. Loeb S, Folkvaljon Y, Makarov DV, Bratt O, Bill-Axelson A, Stattin P. Five-year nationwide follow-up study of active surveillance for prostate cancer. Eur Urol. 2015;67(2):233-238.
14. Hugosson J, Carlsson S, Aus G, et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 2010;11(8):725-732.